Sorafenib combined with TACE improves survival in patients with hepatocellular carcinoma with vascular invasion
{{output}}
Sorafenib is a recommended first-line therapy for advanced hepatocellular carcinoma (HCC). However, when used as monotherapy in patients in advanced stages, the prognosis remains suboptimal. This study aimed to evaluate the impact of transcatheter arterial che... ...
